Saturday, October 31, 2026

Global Chip Rally Leaves Software Behind as Investors Bet on AI Hardware

Micron and Dell each surged 5% on June 25 as investors rotated out of AI software into semiconductor and HPC hardware worldwide. Intel gained 3.8%, SanDisk 4%, while enterprise software stocks fell — a divergence playing out across U.S., Asian, and European markets. The shift signals a global repricing of where AI value is created: in silicon and servers, not applications.

LM Salvado
LM Salvado

June 25, 2026

Global Chip Rally Leaves Software Behind as Investors Bet on AI Hardware
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Micron and Dell each jumped 5% on June 25 as investors globally pivoted from AI software into semiconductor and computing hardware.SanDisk added 4%.1

The Nasdaq Composite fell on the same day — confirming this is a reallocation, not a broad rally.

A Worldwide Infrastructure Bet

The rotation reflects a global consensus: physical AI infrastructure — chips, memory, servers, storage — is the safer bet as the AI application layer matures. This mirrors trends in Asian markets, where chipmakers like Samsung and SK Hynix have outpaced Korean software peers, and in Europe, where semiconductor equipment stocks have held firm.

Taiwan's TSMC remains the linchpin. Demand from U.S. hyperscalers for advanced nodes continues to drive Asian foundry capacity investment, reinforcing the hardware-over-software thesis.

Winners and Losers Across the Stack

Memory leads the winners: Micron and SanDisk both surged on sustained HPC and data centre demand.1 Dell's gains reflect enterprise server orders that cross borders — from U.S. cloud builders to Middle Eastern sovereign AI projects. KLA benefits as semiconductor equipment spending holds globally. Penguin Solutions rose as HPC infrastructure demand expands beyond North America.

Losers: enterprise software vendors and AI services firms dependent on corporate IT budgets. Spending remains constrained in both the U.S. and Europe, squeezing companies monetising AI at the application layer.

Outlook

The rotation is projected to persist three to six months.1 Semiconductor ETFs and AI data centre REITs are positioned to outperform. Fintech and enterprise AI vendors face continued pressure until corporate spending cycles — globally — improve.

For international investors, the signal is consistent: hardware-adjacent positions outperform across markets while enterprise software waits for a budget cycle recovery.

In this story · Knowledge Files

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com